Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis

ObjectiveThe monoclonal antibodies anti-programmed death protein-1 (anti–PD-1) nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for treatment of recurrent/metastatic head and neck carcinoma R/M HNSCC in first line and in platinum refractory disease. This network...

Full description

Bibliographic Details
Main Authors: Andrea Botticelli, Alessio Cirillo, Lidia Strigari, Filippo Valentini, Bruna Cerbelli, Simone Scagnoli, Edoardo Cerbelli, Ilaria Grazia Zizzari, Carlo Della Rocca, Giulia D’Amati, Antonella Polimeni, Marianna Nuti, Marco Carlo Merlano, Silvia Mezi, Paolo Marchetti
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
metastatic head and neck cancer
immunotherapy
anti–PD-1
anti–PD-L1
network meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.705096/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.705096/full

Similar Items